Novo Nordisk Trial Shows No Cognitive Benefit from Ozempic in Alzheimer’s
Novo Nordisk has announced that semaglutide, a widely-used medication for diabetes and weight management, has failed to slow cognitive decline in people with early Alzheimer’s disease. The drug, sold as Ozempic and Wegovy, was tested in individuals with mild cognitive impairment or mild dementia caused by Alzheimer’s. Despite earlier hopes that GLP-1 receptor agonists might […]
Novo Nordisk Trial Shows No Cognitive Benefit from Ozempic in Alzheimer’s Read More »